BRIEF—Change of direction for Fulcrum's leadership

Rare disease company Fulcrum Therapeutics has reappointed its founding chief executive Robert Gould to the top job, on an interim basis.

Dr Gould succeeds Bryan Stuart, who is leaving the company “to pursue other opportunities,” leaving the board to initiate a search for a permanent chief executive.

Board chair Kate Haviland said that during Mr Stuart’s tenure the firm had “demonstrated proof of concept for FTX-6058, initiated a registrational trial in facioscapulohumeral muscular dystrophy (FSHD), and solidified our financial position with multiple successful financings.”

Dr Gould said: “2023 will be a key year for Fulcrum, as we execute on our two clinical programs, FTX-6058 for sickle cell disease and losmapimod for FSHD.”